SARS-CoV-2, the virus that causes COVID-19, attaches to a cellular receptor called angiotensin-converting enzyme 2 (ACE2), and activation of the farnesoid X receptor increases ACE2 expression. New research published in the Journal of Internal Medicine suggests that a drug that inhibits the farnesoid X receptor and is used to treat liver disease may decrease SARS-CoV-2 infections and reduce the severity of COVID-19.
Leave A Comment